Pharmacokinetics (PK) of lonafarnib (L), a farnesyl protein transferase inhibitor.

被引：0
|
作者：
Zhu, Y [1 ]
Statkevich, P [1 ]
Cutler, DL [1 ]
Calzetta, A [1 ]
Curtis, D [1 ]
Batra, VK [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P59 / P59
页数：1
相关论文
共 50 条
  • [1] Effect of food on the pharmacokinetics of lonafarnib, a farnesyl protein transferase inhibitor.
    Zhu, Y
    Statkevich, P
    Cutler, DL
    Pember, L
    Curtis, D
    Batra, VK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P82 - P82
  • [2] Pharmacokinetics of lonafarnib, a farnesyl protein transferase inhibitor, in pediatric patients with brain tumors.
    Zhu, Y
    Statkevich, P
    Curtis, D
    Sugrue, M
    Kieran, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P10 - P10
  • [3] Analogues of cylindrol A, a novel farnesyl protein transferase inhibitor.
    Cermak, SC
    Wilson, JM
    Wiemer, DF
    Hohl, RJ
    LewisTibesar, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 55 - MEDI
  • [4] Resistance to the Farnesyl transferase inhibitor SCH66336/Lonafarnib caused by mutations in the target protein Farnesyl transferase beta.
    Raz, T
    Mohammad, A
    Daley, GQ
    BLOOD, 2004, 104 (11) : 133A - 133A
  • [5] The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2
    Wang, EJ
    Johnson, WW
    CHEMOTHERAPY, 2003, 49 (06) : 303 - 308
  • [6] Inhibition of angiogenin induced corneal angiogenesis by a Farnesyl transferase inhibitor.
    Park, YH
    Chung, SK
    Lee, JY
    Joo, CK
    Baek, NH
    Kim, JH
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S833 - S833
  • [7] Heteronemin as a protein farnesyl transferase inhibitor
    Ledroit, V
    Debitus, C
    Ausseil, F
    Raux, R
    Menou, JL
    Hill, BT
    PHARMACEUTICAL BIOLOGY, 2004, 42 (06) : 454 - 456
  • [8] Synthesis and metabolism of two isotopomers of a C-14 labeled farnesyl-protein transferase inhibitor.
    Elmore, CS
    Dean, DC
    Marks, TM
    Braun, MP
    Yu, NX
    Zhang, Y
    Raab, CE
    Singh, R
    Jin, LX
    Melillo, DG
    Dinsmore, CJ
    Williams, TM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U29 - U29
  • [9] Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling
    Meier, F. E.
    Niessner, H.
    Flaherty, K.
    Schadendorf, D.
    Sinnberg, T.
    Schittek, B.
    Garbe, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] The farnesyl transferase inhibitor Lonafarnib sensitizes melanoma cells to the multikinase inhibitor Sorafenib by inhibiting Rheb farnesylation and mTOR signaling
    Niessner, H.
    Sinnberg, T.
    Schwarz, D.
    Kulms, D.
    Lasithiotakis, K.
    Maczey, E.
    Garbe, C.
    Meier, F.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (02) : 205 - 205
12345